Gauteng is set to roll out Lenacapavir, a new long-acting HIV prevention injection, targeting over 56,000 individuals at high risk of HIV infection.

Limited supplies threaten potential positive effect of HIV prevention drug lenacapavir

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa